MMP2 and prostate cancer: The overall results of meta-analysis showed that an elevated risk of the disease was implicated in MMP-2-1306 C/T polymorphism under two genetic models (CT vs. CC: OR = 1.78, 95% CI = 1.33–2.38; TT+CT vs. CC: OR = 1.62, 95% CI = 1.24–2.12) and no significant association was observed between MMP-1-1607 1G/2G polymorphism and the risk of prostate cancer.